Novartis Organizational Structure & Org Chart

Novartis's public structure is best understood through Cardiovascular, Renal and Metabolic, Immunology, Neuroscience, Oncology. The interactive chart is a researched, editable map of those published areas.

Novartis organizational chart

Edit this organizational chart

Novartis's reporting structure as of 2026-09. Drag to pan, scroll to zoom — or open it in QueryChart and edit it as your own.

Industry: Innovative medicines
Headquarters: Basel, Switzerland
Founded: 1996
CEO: Vas Narasimhan
Ownership: Public
Structure as of: 2026-09
Structure last reviewed: 2026-09-29

About the company

Novartis is a innovative medicines organization. Its current public materials identify Cardiovascular, Renal and Metabolic, Immunology, Neuroscience, Oncology as useful ways to understand its activities. After separating Sandoz, Novartis focuses on innovative medicines and publicly identifies four core therapeutic areas. These areas explain the portfolio without inventing separate legal subsidiaries for each drug program.

This QueryChart tree puts those disclosed areas next to a single, separately marked leadership branch for Vas Narasimhan. The business branches describe a public portfolio, not a confidential employee hierarchy. A line between a category and an offering means the offering belongs in that published category; it does not say that a particular executive personally manages every team shown.

Published businesses and operating areas

Cardiovascular, Renal and Metabolic is one of the visible areas in Novartis's published structure. This therapeutic area targets heart, kidney and metabolic diseases. The editable chart places Cardiovascular and Renal and metabolic beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

Immunology is one of the visible areas in Novartis's published structure. Immunology research and medicines address immune-mediated conditions. The editable chart places Immune diseases and Immunology development beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

Neuroscience is one of the visible areas in Novartis's published structure. Neuroscience programs target diseases of the nervous system. The editable chart places Neurological medicines and Neuroscience research beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

Oncology is one of the visible areas in Novartis's published structure. Cancer medicines include established therapies and advanced platforms. The editable chart places Oncology medicines and Radioligand therapy beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

Key leadership roles

Vas Narasimhan
Chief executive officer

How this structure supports the business

The Cardiovascular, Renal and Metabolic and Immunology branches answer different questions about Novartis. This therapeutic area targets heart, kidney and metabolic diseases. Immunology research and medicines address immune-mediated conditions. Showing them side by side is more informative than drawing an unsupported chain of managers, particularly when the public materials report a portfolio or service line rather than a complete internal org chart.

After separating Sandoz, Novartis focuses on innovative medicines and publicly identifies four core therapeutic areas. These areas explain the portfolio without inventing separate legal subsidiaries for each drug program. Neuroscience programs target diseases of the nervous system. The diagram makes that distinguishing feature visible while keeping the named leadership layer separate. It is useful as a starting point for an editable company chart; users can replace the public groupings with their own teams, roles and verified reporting relationships.

Advantages and disadvantages

The Cardiovascular, Renal and Metabolic branch uses a publicly described company-specific grouping.: A portfolio branch does not prove an individual reporting line.
The chart distinguishes Immunology from Neuroscience.: A single-parent tree cannot show every cross-business collaboration or legal-entity link.

Interesting facts

Novartis's public materials identify Cardiovascular, Renal and Metabolic as a major area.
Immunology includes Immune diseases and Immunology development in this educational map.
Neuroscience is shown separately because neuroscience programs target diseases of the nervous system.
The principal leadership role is identified as Vas Narasimhan.

Related process templates

Related organization charts

Frequently asked questions

How is Novartis organized?

This educational chart maps Cardiovascular, Renal and Metabolic, Immunology, Neuroscience, Oncology, using the company's public materials. It does not attempt to reproduce a full internal employee hierarchy.

Who leads Novartis?

Vas Narasimhan is the publicly identified chief executive officer in the sources reviewed on 29 September 2026.

Is this an official Novartis org chart?

No. It is an independent reconstruction of public business categories and leadership information, with simplified connections for exploration and editing.

Use this org chart template

Open this Novartis structure in QueryChart and rename roles, add departments, remove areas or change connections for your own organization.